What is JNJ's current stock price?

As of now, JNJ is trading at $190.40, with a daily change of -1.08%.

What are the risks associated with JNJ stock?

JNJ Key risk is its Low Risk Level, .

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

JNJ Stock Analysis & IQ Rating | Johnson & Johnson

JNJ

Johnson & Johnson

$190.40

-$2.07 | -1.08%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 194.48

MKT CAP

$ 458.73B

52W Low

$ 140.68

VOL

$ 4.59M

P/E Ratio

18.38

AVG VOL

$ 8.88M

RSI

62.27

TREND

Uptrend

JNJ Stock IQ

Login to see Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

JNJ Target Price

Login to display

Strengths

JNJ Rewards

Earnings are forecast to grow

JNJ Rewards

Upgraded on attractively valued

JNJ Rewards

Investors confidence is positive

JNJ Rewards

Pays a reliable dividend

Chart

$181.62 (+4.83%)

$167.33 (+13.79%)

$153.22 (+24.27%)

$156.73 (+21.48%)

1year

6month

3month

1month

JNJ Risk Level

JNJ has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

LOW

HIGH

JNJ Analysts Opinion

JNJ overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

JNJ Analysts Opinion

JNJ Analysts opinion is positive and also has improved from the past 3 months

JNJ Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

82%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

81%

JNJ Street Opinion

JNJ Street view is extremely bullish and have positive views on the near-term outlook

JNJ Performance Sentiment

Sentiments overview associated with JNJ events and the stock performance.

82%

17%

Positive

Negative

59 out of 72
events present

12 out of 72
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$191.80

Resistance
Price

$177.73

Current Price Range

$193.72

Show methods +

Linked to JNJ

IQ

Close Price

Change

SNDX

2.45

13.53

-7.83%

REGN

4.01

577.95

+0.39%

PFE

4.08

24.76

+0.36%

PCRX

2.04

21.82

+0.23%

NBTX

3.50

19.20

-0.52%

JNJ Latest Analysis +

Johnson & Johnson Reports Strong 52-Week Data For Oral Psoriasis Drug Icotrokinra . (RTTNews) - Johnson & Johnson (JNJ) released new 52-week Phase 3 results from the ICONIC-TOTAL study evaluating icotrokinra a first-in-class oral peptide that selectively blocks the IL-23 receptor in adults and adolescents (12) with plaque psoriasis (PsO) affecting high-impact

Today

$190.40 | -1.08%

Earnings

Notable ETF Outflow Detected - JEPI ABBV JNJ ROST. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the JPMorgan Equity Premium Income ETF (Symbol: JEPI) where we have detected an approximate $195.6 million dollar outflow -- thats a 0.5% decrease week

Wed Oct 22, 2025

$192.94 | +0.55%

Potential

Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm. RA'.ANANA Israel Oct. 21 2025 (GLOBE NEWSWIRE) -- Inspira™. Technologies OXY B.H.N. Ltd. (NASDAQ:) (".Ms. Sivan Matza is a Director at a leading international investment management firm overseeing tens of billions of dollars in assets. Her extensive experience in global finance regulation and accounting strengthens Inspira'.s g

Tue Oct 21, 2025

$191.88 | -0.94%

Activity

Johnson & Johnson Draws Long-Term Buyers as Markets Turn Cautious. Key PointsAdded 91615 shares in Johnson &. Johnson. estimated transaction value of ~$15.70 million

Tue Oct 21, 2025

$191.88 | -0.94%

Activity

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026. J&J projects faster 2026 growth in Innovative Medicine and MedTech topping consensus estimates on both revenues and EPS.

Tue Oct 21, 2025

$191.88 | -0.94%

Potential

Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm. RA'.ANANA Israel Oct. 21 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (

Tue Oct 21, 2025

$191.88 | -0.94%

Activity

Should You Buy Sell or Hold J&J Stock After Robust Q3 Earnings?. JNJs strong Q3 results upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

Fri Oct 17, 2025

$193.22 | +0.58%

Earnings

Johnson & Johnson succeeds in late-stage multiple myeloma trial.

Thu Oct 16, 2025

$192.12 | +0.48%

Activity

Jury Orders Johnson & Johnson (JNJ) to Pay $966M in Talc Verdict. Johnson &. Johnson (NYSE:JNJ) is one of Ray Dalios latest top stock positions. On October 7 a Los Angeles jury ordered Johnson &. Johnson (NYSE:JNJ) to pay $966 million to the family of a California woman who died from mesothelioma. This was after the jury found the companys talc-based baby powder caused the womans cancer. [….]

Thu Oct 16, 2025

$192.12 | +0.48%

Potential

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy. On Thursday ) announced positive topline results . The company’.s Phase 3 MajesTEC-3 trial is evaluating Tecvayli (teclistamab-cqyv) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for patients with relapsed or refractory multiple myeloma who received one to three prior treatments.After nearly three years of follow-up the Tecvayli-Darzalex combination significantly improved both progressi

Thu Oct 16, 2025

$192.12 | +0.48%

Earnings

FAQ About JNJ Stock Insights

What is JNJ current stock price?

What are JNJ stock strengths?

What risks are associated with JNJ stock?

When is JNJ next earnings report?

What is JNJ market cap and volume?

What is JNJ's current Stock IQ?

Should I buy JNJ stock right now?

Is JNJ a Strong Buy right now?

What does a 'Strong Buy' rating mean for JNJ?

What does a 'Strong Sell' rating mean for JNJ?

What factors influence JNJ's Stock IQ?

Explore our JNJ Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored JNJ Stock Strategies
Effective Risk Management

FIND US ON

Receive our JNJ Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

JNJ

Johnson & Johnson

Current Price

$190.40

-$2.07 | -1.08%

52W High

$ 194.48

MKT CAP

$ 458.73B

52W Low

$ 140.68

VOL

$ 4.59M

P/E Ratio

18.38

AVG VOL

$ 8.88M

RSI

62.27

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

JNJ Rewards

Earnings are forecast to grow

JNJ Rewards

Upgraded on attractively valued

JNJ Rewards

Investors confidence is positive

JNJ Rewards

Pays a reliable dividend

Linked to JNJ

Symbol

IQ

Close

Change

SNDX

2.45

13.53

-7.83%

REGN

4.01

577.95

+0.39%

PFE

4.08

24.76

+0.36%

PCRX

2.04

21.82

+0.23%

NBTX

3.50

19.20

-0.52%

JNJ Stock IQ

Login to unlock Johnson & Johnson (JNJ) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$181.62 (+4.83%)

$167.33 (+13.79%)

$153.22 (+24.27%)

$156.73 (+21.48%)

1year

6month

3month

1month

JNJ Analysts Opinion

JNJ Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

JNJ Analysts Opinion

JNJ Analysts opinion is positive and also has improved from the past 3 months

JNJ Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

82%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

81%

JNJ Street Opinion

JNJ Street view is extremely bullish and have positive views on the near-term outlook

JNJ Risk Level

JNJ has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

LOW

HIGH

JNJ Performance Sentiment

Sentiments overview associated with JNJ events and the stock performance.

82%

17%

Positive

Negative

59 out of 72
events present

12 out of 72
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$191.80

Resistance
Price

$177.73

Current Price Range

$193.72

Show methods +

JNJ Latest Analysis

Johnson & Johnson Reports Strong 52-Week Data For Oral Psoriasis Drug Icotrokinra . (RTTNews) - Johnson & Johnson (JNJ) released new 52-week Phase 3 results from the ICONIC-TOTAL study evaluating icotrokinra a first-in-class oral peptide that selectively blocks the IL-23 receptor in adults and adolescents (12) with plaque psoriasis (PsO) affecting high-impact

Today

$190.40 | -1.08%

Earnings

Notable ETF Outflow Detected - JEPI ABBV JNJ ROST. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the JPMorgan Equity Premium Income ETF (Symbol: JEPI) where we have detected an approximate $195.6 million dollar outflow -- thats a 0.5% decrease week

Wed Oct 22, 2025

$192.94 | +0.55%

Potential

Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm. RA'.ANANA Israel Oct. 21 2025 (GLOBE NEWSWIRE) -- Inspira™. Technologies OXY B.H.N. Ltd. (NASDAQ:) (".Ms. Sivan Matza is a Director at a leading international investment management firm overseeing tens of billions of dollars in assets. Her extensive experience in global finance regulation and accounting strengthens Inspira'.s g

Tue Oct 21, 2025

$191.88 | -0.94%

Activity

Johnson & Johnson Draws Long-Term Buyers as Markets Turn Cautious. Key PointsAdded 91615 shares in Johnson &. Johnson. estimated transaction value of ~$15.70 million

Tue Oct 21, 2025

$191.88 | -0.94%

Activity

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026. J&J projects faster 2026 growth in Innovative Medicine and MedTech topping consensus estimates on both revenues and EPS.

Tue Oct 21, 2025

$191.88 | -0.94%

Potential

Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm. RA'.ANANA Israel Oct. 21 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (

Tue Oct 21, 2025

$191.88 | -0.94%

Activity

Should You Buy Sell or Hold J&J Stock After Robust Q3 Earnings?. JNJs strong Q3 results upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

Fri Oct 17, 2025

$193.22 | +0.58%

Earnings

Johnson & Johnson succeeds in late-stage multiple myeloma trial.

Thu Oct 16, 2025

$192.12 | +0.48%

Activity

Jury Orders Johnson & Johnson (JNJ) to Pay $966M in Talc Verdict. Johnson &. Johnson (NYSE:JNJ) is one of Ray Dalios latest top stock positions. On October 7 a Los Angeles jury ordered Johnson &. Johnson (NYSE:JNJ) to pay $966 million to the family of a California woman who died from mesothelioma. This was after the jury found the companys talc-based baby powder caused the womans cancer. [….]

Thu Oct 16, 2025

$192.12 | +0.48%

Potential

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy. On Thursday ) announced positive topline results . The company’.s Phase 3 MajesTEC-3 trial is evaluating Tecvayli (teclistamab-cqyv) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for patients with relapsed or refractory multiple myeloma who received one to three prior treatments.After nearly three years of follow-up the Tecvayli-Darzalex combination significantly improved both progressi

Thu Oct 16, 2025

$192.12 | +0.48%

Earnings

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of JNJ. We're here to help you make informed investment decisions today.

FIND US ON

Receive our JNJ Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

JNJ Stock trends

JNJ Stock performance

JNJ Stock analysis

JNJ investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing JNJ

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing JNJ

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

JNJ Stock Analysis & IQ Rating | Johnson & Johnson

JNJ Stock IQ

JNJ Target Price

JNJ Risk Level

JNJ Analysts Opinion

JNJ Street Consensus

JNJ Performance Sentiment

Technical Price Levels

Explore our JNJ Stock insights

Receive our JNJ Daily Alerts

JNJ Stock IQ

JNJ Street Consensus

JNJ Risk Level

Technical Price Levels

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of JNJ. We're here to help you make informed investment decisions today.

Receive our JNJ Daily Alerts

JNJ Runner Alarm